摘要
ImageCHICAGO—For patients with platinum-resistant recurrent ovarian cancer, a combination of bevacizumab and standard-of-care chemotherapy cuts the risk of disease progression almost in half compared with chemotherapy alone. This and other outcomes from the randomized Phase III AURELIA trial from France were described here at the American Society of Clinical Oncology Annual Meeting (Abstract LBA5002). But in a provocative turn, the Discussant for the study recommended stopping Phase III trials of molecularly targeted agents in ovarian cancer because there are no large groups of homogeneously genomically defined patients with serous cancer, and because there is no strong predictive biomarker in epithelial ovarian cancer. New Standard Option “Bevacizumab combined with chemotherapy should be considered a new standard option in platinum-resistant ovarian cancer,” said Eric Pujade-Lauraine, MD, PhD, who presented the data on behalf of the AURELIA investigators and the Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). He said the results are very significant because the addition of bevacizumab offers a new treatment option for the 20 percent of women who have primary platinum-resistant disease, as well as those whose disease later becomes platinum resistant. Pujade-Lauraine, Professor of Medicine at Université Paris Descartes, said AURELIA is the first randomized Phase III trial in platinum-resistant ovarian cancer to demonstrate benefit with biologic therapy and benefit with a combination regimen vs. monotherapy. He noted that bevacizumab efficacy with platinum in front-line therapy has already been demonstrated in the Gynecologic Oncology Group 0218 and ICON7 studies, and efficacy in relapsed, platinum-sensitive disease was demonstrated in the OCEANS study. Standard therapy for recurrent platinum-resistant disease is single-agent chemotherapy. “Bevacizumab is an anti-VEGF antibody and it is effective in ovarian cancer because that is a highly VEGF-driven disease,” he said. Women eligible for inclusion in the study had to have ovarian cancer that progressed within six months of completing at least four cycles of platinum-based therapy and to have had no history of bowel complications. Chemotherapies in the combination were paclitaxel, pegylated liposomal doxorubicin, or topotecan. A total of 361 women were randomly assigned to receive standard chemotherapy alone (182 patients) or in combination with bevacizumab (179) until disease progression or unacceptable toxicity. Those in the control arm could cross over to bevacizumab monotherapy at disease progression.ERIC PUJADE-LAURAINE, MD, PHD: “Bevacizumab is an anti-VEGF antibody and it is effective in ovarian cancer because that is a highly VEGF-driven disease.”Median follow-up was 13.5 months for women receiving standard chemotherapy and 13 months for the bevacizumab group. The principal finding was that median progression-free survival was 3.4 months for patients receiving standard chemotherapy alone vs. 6.7 months for those receiving bevacizumab, with a hazard ratio of 0.48. The combination improved PFS regardless of age, the relapse-free interval, the extent of disease, the presence of ascites, or the type of chemotherapy administered, Pujade-Lauraine reported. The 12.6 percent response rate in the standard-chemotherapy group was about what was expected in this patient population, compared with the significant improvement response rate in the bevacizumab-treated group, he said. Toxicity Profiles He said the toxicity profile of bevacizumab was similar to that seen in previous trials: hypertension grade 2 and above was more frequent in the bevacizumab arm, 20.1 percent vs. 6.6 percent; proteinuria grade 2 and above was also more frequent in the bevacizumab-treated group—10.6 vs. 0.6 percent.MICHAEL SEIDEN, MD, PHD: “The genomics of serous cancer argue against Phase III trials….In addition, there is no strong predictive biomarker—not even a good mediocre predictive biomarker—in epithelial ovarian cancer.”The rates of fatigue, abdominal pain, vomiting, and dyspnea were lower in the bevacizumab group. As expected, peripheral sensory neuropathy and hand-foot syndrome of at least Grade 3 was higher in the bevacizumab arm. Pujade-Lauraine speculated that this was perhaps because more patients were responding and received more chemotherapy. From past experience with bevacizumab the investigators were concerned about intestinal perforation, he said. In this study the Grade 2 and above perforation rates were 1.7 percent for bevacizumab and none with chemotherapy alone. Grade 2 and above fistula/abscess occurred in 2.2 percent of the bevacizumab patients vs. none in the chemotherapy-alone arm. But, he added, patients at high risk of GI perforation were excluded from the study based on a history of bowel obstruction or abdominal fistula or clinical or radiological evidence of rectosigmoid involvement. He noted in an interview that he warns colleagues not to use the new bevacizumab-chemotherapy regimen in such patients. Bevacizumab is made by Genentech-Roche. The majority of AURELIA investigators, including Dr. Pujade-Lauraine, disclosed consultant or advisory roles or research funding from Roche Diagnostics. Discussant: Radical Suggestion The Discussant for the study, Michael Seiden, MD, PhD, President and Chief Executive Officer of Fox Chase Cancer Center, made a radical suggestion: In this time of rigorous cost constraints, he said, researchers should stop all randomized Phase III trials of molecularly targeted agents in ovarian cancer. Successful Phase III trials of targeted agents require enrolling large groups of patients with similar molecular characteristics. But “the genomic data in ovarian cancer are overwhelming that there are not large groups, not even medium-size groups, of homogeneously genomically defined patients within the most common category, serous cancer,” he said. “The genomics of serous cancer argues against Phase III trials.” In addition, he said, essentially every successful Phase III or randomized Phase II study that has led to FDA approval of a molecularly targeted drug has had an undeniably powerful biomarker, such as HER-2 amplification, BCR-ABL translocation, or PFL-RAR translocation. “But there is no strong predictive biomarker—not even a good mediocre predictive biomarker—in epithelial ovarian cancer,” he said. Seiden speculated that it would take “deep sequencing” of DNA from 10,000 patients with a single histologic subtype of ovarian cancer to find even a small group of genomically homogeneous patients. “Would it be reasonable to require that all trials of molecular targeted agents, regardless of what the agent is, first be required to submit the full genomics of patients entering clinical trial?” he asked. “With the plummeting costs of genomic sequencing, this wouldn't add a dramatic amount of dollars to the cost of clinical trials in the not too distant future.” He went even further, suggesting that insurers or the Centers for Medicare & Medicaid Services shouldn't pay for clinical care of patients with epithelial ovarian cancer until the genome of the patient has been submitted. “We should consider redistributing some of our research investment more broadly towards prevention, immunotherapy and the biology that underpins tumor initiation,” he said.